10x Genomics TXG
United StatesHealthcare · Medical DevicesUSD
66.00 USD (−13.3%)
15 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
10x Genomics is a health technology company that develops and sells instruments and reagents for genomic research, enabling single-cell and spatial analysis at scale. 10x Genomics shows very weak financial health (Net Debt/EBITDA of 11.49) and negative profitability (ROE of -9.40%), with declining revenue (-12.70%).
Key points
from its scores- ✓Good share-price trend9.8
- ✕Little or no dividend0.5
- ✕Weak growth1.3
- ✕Unfavourable risk and backdrop2.1
AI analysis
bottom line, main risk, context and newsThe combination of very high leverage, negative profitability, and declining revenue makes the stock extremely risky despite the recent price momentum.
Despite strong stock momentum (497.99), the fundamentals do not support the current valuation (forward P/E of 992.57).
The main risk is financial sustainability: with a Net Debt/EBITDA of 11.49 and an operating margin of -15.20%, the company needs a drastic operational improvement to avoid solvency issues.
Context and risks
No recent relevant news and no material exposure to current macro factors (rates, oil, tariffs) that directly affect its genomics instruments business. The main risk is operational and business model related, not contextual.
Is 10x Genomics stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 370% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 12.0 | 4.1 | +192% |
| Price / sales | 16.1 | 3.4 | +370% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 2.2 out of 10 (median for Healthcare: 4.7).
Average analyst target: 66.00 USD, −13.3% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 3.1 (sector 5.5), Growth 1.3 (sector 6.6).
Classic formulas with standard assumptions (5.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 992.6
- EV / EBITDA
- −229.2
- Price / book
- 12.0
- Price / sales
- 16.1
- Market cap
- 9.9B USD
- Enterprise value
- 9.4B USD
Profitability
- ROE
- −9.4%
- ROA
- −5.0%
- ROIC (approx.)
- −10.4%
- Gross margin
- 70.1%
- Operating margin
- −15.2%
- Net margin
- −12.2%
- Free cash flow
- 179.7M USD
- FCF yield
- 1.8%
Solvency
- Total debt
- 78.8M USD
- Net debt
- −473.2M USD
- Cash
- 552.0M USD
- EBITDA
- −41.2M USD
- Net debt / EBITDA
- 11.49
- Debt / equity
- 9.54
- Current ratio
- 5.69
- Quick ratio
- 5.08
Growth
- Revenue growth
- −12.7%
- EPS (TTM)
- −0.59 USD
- EPS (forward)
- 0.08 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 1.99
- Analyst consensus
- Buy (15)
- Target price
- 66.00 USD
- 52-week range
- 11.16 – 102.81
Recent news
All TXG news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about 10x Genomics
Is 10x Genomics stock cheap or expensive?
On Price / sales, it trades 370% above the Healthcare median. Valuation score: 2.2 out of 10 (median for Healthcare: 4.7). Average analyst target: 66.00 USD, −13.3% versus the price. This is not investment advice.
What score does 10x Genomics get on MeridIAn Screener?
It scores 2.7 out of 10, rank 2,103 of 2,130 (better than 1% of the companies analysed). Its strongest category is Momentum (9.8) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is 10x Genomics worth on the stock market?
Its market capitalisation is 9.9B USD and its enterprise value, debt included, is 9.4B USD.
How much debt does 10x Genomics have?
It has more cash than debt: net cash of 473.2M USD.
Does 10x Genomics pay a dividend?
It pays no dividend, or almost none.
How has 10x Genomics stock performed over the last year?
It has risen 563.5% over the last year, excluding dividends. Over the last 52 weeks it has traded between 11.16 and 102.81 USD. Past performance does not guarantee future results.
What do analysts think of 10x Genomics?
15 analysts cover it; their average recommendation is “Buy” and their average target is 66.00 USD (−13.3% versus the price). It is an estimate, not market data.